Duration of protection and age-dependence of the effects of the SPf66 malaria vaccine in African children exposed to intense transmission of Plasmodium falciparum.
The SPf66 synthetic vaccine is safe and partly efficacious against Plasmodium falciparum malaria among children 1-5 years old. The estimated vaccine efficacy [VE] for all clinical episodes over a period of 18 months after the third dose is 25% (95% confidence interval [CI], 1%-44%; P = .044). The observed temporal variations in efficacy could have been due to chance (likelihood ratio chi 2 = 13.8, 8 df; P = .086). Efficacy against clinical malaria did not vary significantly with age (chi 2 = 1.07, 4 df; P = .90). Overall parasite density was 21% lower in vaccine recipients than in the placebo group (95% CI, 0%-38%; P = .044). Further development of SPf66 may require trials to evaluate safety, immunogenicity, and efficacy when administered in the first year of life, together with other vaccines contained in the Expanded Programme of Immunization schedule.
Alonso
P L
PL
Unidad de Epidemiologia y Bioestadistica, Hospital Clinic, Barcelona, Spain.
Smith
T A
TA
Armstrong-Schellenberg
J R
JR
Kitua
A Y
AY
Masanja
H
H
Hayes
R
R
Hurt
N
N
Font
F
F
Menendez
C
C
Kilama
W L
WL
Tanner
M
M
D000367:Age Factors; D002675:Child, Preschool; D003430:Cross-Sectional Studies; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D007223:Infant; D017780:Malaria Vaccines / Q000627:therapeutic use*; D016778:Malaria, Falciparum / Q000097:blood / Q000453:epidemiology / Q000517:prevention & control* / Q000635:transmission; D011159:Population Surveillance; D015800:Protozoan Proteins / Q000627:therapeutic use*; D011994:Recombinant Proteins; D013636:Tanzania / Q000453:epidemiology; D013997:Time Factors; D014614:Vaccines, Synthetic / Q000627:therapeutic use*
D017780:Malaria Vaccines; D015800:Protozoan Proteins; D011994:Recombinant Proteins; C066269:SPf66 protein, Plasmodium; D014614:Vaccines, Synthetic